Daewoong Pharmaceutical’s’Hoystar tablet’ approved for phase 3 clinical trials for COVID-19 prevention effect
Daewoong Pharmaceutical’s’Hoystar tablet’ confirmed the possibility of COVID-19 treatment in phase 2a clinical trial
